|
|
|
|
||
Re: Stifel bumped their target to $18, believes dividend is safe at $2, maintains Outperform Note Steifel reiterates what Mike noted in the CC about higher B/V: We continue to think NRZ's valuation is attractive at 1.08x trailing GAAP book value. Management presented some detail on a rough earnings range for its ancillary business segments (including Covius, Guardian, and the operating earnings generated from servicing) of $250-$400 million per year. Since those businesses are marked at cost in NRZ's GAAP book value, we think their fair |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
3412 | Re: Stifel bumped their target to $18, believes dividend is safe at $2, maintains Outperform | rlp2451 | 1 | 2/13/2020 9:19:42 AM |